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A B S T R A C T
Objectives: Many in vitro fertilization (IVF) complications are inflammatory by nature, some of which are
even life-threatening. We evaluated the response of C-reactive protein (CRP) in IVF complications,
especially in early and late ovarian hyperstimulation syndrome (OHSS), to support clinical decision
making in gynecological emergency policlinics.
Study design: In a prospective two-year study at Helsinki University Hospital, Finland, we recruited
patients with IVF complications including moderate or severe OHSS (n = 47 patients: 36 early and 14 late
OHSS cases), or other IVF complications (n = 13). As controls, we recruited women in an uncomplicated
IVF cycle (n = 27). Serial blood samples (CRP, blood count, platelets, albumin, estradiol, creatinine, and
electrolytes) were collected from patients upon admission to the emergency polyclinic and during and
after treatment on the ward, and from the controls prior, during, and after the IVF protocol. All samples
were categorized according to oocyte pick-up (OPU). The statistics included comparisons between and
within the study groups, and receiver-operating characteristic (ROC) curve analysis for diagnostic
accuracy of CRP for early OHSS at emergency polyclinics.
Results: On admission, CRP did not differentiate OHSS from other IVF complications, but CRP was higher
in early (median 21; IQR 8–33 mg/L) than in late (6; 3–9 mg/L, p = 0.001) OHSS. In ROC analysis for CRP
(12 mg/L), the area under the curve (AUC) was 0.74 (p = 0.001) with sensitivity of 69% and specificity of
71% for early OHSS. CRP was significantly higher (28; 10–46 mg/L) in patients with early OHSS two days
after oocyte pick-up (OPU) than in the controls (5; <3–9 mg/L, p < 0.001). The level normalized by
12 days, similarly to the controls. On the ward, the peak CRP was higher if early OHSS was complicated
with infection (108; 49–166 mg/L) than without infection (20; 8–32 mg/L, p = 0.001). Late OHSS was
associated with hypoalbuminemia (19.6; 16.2–23.1 g/L, p < 0.001) and thrombocytosis (494; 427–561
E9/L, p = 0.004; comparisons to early OHSS).
Conclusions: Early OHSS associates with a distinct rise in CRP level beyond that induced by
uncomplicated oocyte pick-up, whereas the CRP levels in late OHSS are comparable to those in the
control cycles. CRP identifies, but cannot distinguish IVF complications.
 2016 Elsevier Ireland Ltd. All rights reserved.Introduction
The complications of in vitro fertilization (IVF) treatment
include ovarian hyperstimulation syndrome (OHSS), intra-abdom-
inal hemorrhage, ovarian torsion, spontaneous cyst rupture,
infections and thromboembolism [1]. Many of these complications* Corresponding author at: PO Box 140 (Haartmaninkatu 2), FIN-00290 Helsinki,
Finland. Fax: +358 9 4717 4801.
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http://dx.doi.org/10.1016/j.ejogrb.2016.10.051
0301-2115/ 2016 Elsevier Ireland Ltd. All rights reserved.involve inflammation and quite similar symptoms consisting of
abdominal pain, distension, diarrhea, vomiting, fever and/or
dyspnea. The most prevalent complication is the potentially life-
threatening OHSS that emerges in around 0.5–5% of IVF cycles
[2]. Ultrasonography reveals enlarged cystic ovaries and intra-
abdominal fluid. However, data on the role of laboratory tests in
differential diagnosis of these complications are scarce.
Early OHSS is triggered by injected human chorionic gonado-
trophin (hCG), and the symptoms usually start within a week after
oocyte pick-up (OPU), whereas late OHSS is associated with early
production of hCG due to pregnancy with symptoms exaggerating
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symptoms and laboratory findings, OHSS is classified as mild,
moderate, severe, or critical [4]. Hematocrit is considered the best
indicator of the severity of the syndrome [5], but leukocytosis,
hypoproteinemia, and hyponatremia also associate with severe
forms of OHSS [6]. Ovarian torsion and the rupture of an ovarian
cyst may occur with OHSS, with symptoms of unilateral pain and
anemia [7,8]. Described risk factors for OHSS include young age,
polycystic ovarian syndrome [9], high antral follicle count and
anti-Müllerian hormone level [10], but OHSS is still difficult to
predict and prevent [11,12].
C-reactive protein (CRP), an acute phase protein produced by
the hepatocytes, is a marker of systemic inflammation, tissue
damage, and/or infection [13]. CRP measurement is of value in
differential diagnosis for bacterial and viral infections and
postoperative complications [14]. CRP has been suggested to
exclude concomitant infection in OHSS [7]. However, the effect of
OPU on CRP in high-response IVF cycles and the role of CRP in the
differential diagnosis of IVF complications are unclear. The aim of
this study was to assess the CRP response in conjunction with other
routine laboratory parameters as an indicator of IVF complications,
especially early OHSS.
Material and methods
This prospective cohort study of IVF patients was conducted at
Helsinki University Hospital, Department of Obstetrics and
Gynecology, Finland in 2006–08, approved by the local Ethical
Committee. The study complies with the Strobe criteria [15]. Sixty-
five women with OHSS symptoms were recruited from the
outpatient emergency polyclinic with informed consent. We
excluded five patients with mild OHSS, as only moderate and
severe forms do need special care and treatment [4,9]. Thus we had
60 acute patients, with referral either from private clinics (68%) or
from our IVF unit. Forty-seven patients had OHSS, and 13 some
[(Fig._1)TD$FIG]Fig. 1. Flow-chart of the recruitment and classification of patients in the study. IVF: in vitr
early and late OHSS. **Gastroenteritis or unexplained pain.other IVF complication. Three patients had admissions both as
early and late OHSS, resulting in 50 OHSS cases: 36 (72%) early and
14 (28%) late OHSS (Fig. 1).
Data on patient characteristics, medical history, infertility
treatments, and symptoms were retrieved through a structured
questionnaire and medical records. The physician on duty did a
gynecological and ultrasound examination, an X-ray in the case of
dyspnea, and made the decisions about hospitalizing (n = 47, 78%)
or discharging the patient, treatment with intravenous fluids,
drainage of ascites and pleural fluid. A voluntary follow-up visit a
week after discharge was offered to those hospitalized (n = 42,
89%).
OHSS was combined with another diagnosis in eight cases (four
pelvic and two urinary infections, two suspected ovarian torsions).
Fever (38 8C) with intense abdominal pain was regarded as an
infection. The severity of OHSS was graded by common criteria [4]
and we identified the symptomatically worst day during hospital-
ization (dyspnea, fever, diminished diuresis, maximum waist
circumference, weight, and drainage of ascites or pleural fluid).
As controls, we recruited 30 infertile women, from our IVF unit
with informed consent, who had a possible risk factor (Table 1) for
developing OHSS [16] when signing up for their IVF cycle or at
timing of OPU. All women were treated with a standard (reduced
doses) long gonadotrophin releasing hormone agonist protocol
[17], as the antagonist protocol had not yet been introduced in
practice at our IVF unit. Three patients developed OHSS, resulting
in 27 controls.
All blood samples were categorized as days after OPU (OPUd).
Samples including serum and plasma for freezing (80 8C) were
collected from the acute patients on admission, daily or every other
day on the ward, and at the follow-up visit; and from the controls
prior (mid-luteal phase), repeatedly during (10th day of stimula-
tion, OPU, OPU2, OPU7, OPU14) and after IVF cycle (OPU35).
All parameters were measured with accredited methods at the
Helsinki University Hospital Laboratory (HUSLAB). For CRPo fertilization; OHSS, ovarian hyperstimulation syndrome. *Three patients had both
Table 1
The patient characteristics. The data are expressed as number of patients (%), or mean standard deviation.
Control cyclea Early OHSS Late OHSS Other IVF complication
n 27 36 14 13 p-Value
Age (years) 34.02.4* 31.64.4* 34.53.6 34.14.1 0.019
BMI (kg/m2) 23.63.5 22.23.2 21.62.7 23.33.9 0.284
Smoking 2 (7) 1 (3) 1 (7) 2 (15) 0.477
Duration of Infertility (years) 4.62.8 4.22.4 2.81.3 4.63.3 0.181
Etiology 0.110
Male 4 (15) 9 (25) 5 (36) 0
Female 6 (22) 9 (25) 6 (43) 6 (46)
Combined 7 (26) 8 (22) 0 1 (8)
Unexplained 10 (37) 8 (22) 3 (21) 6 (46)
Ovum donor 0 2 (6) 0 0
Risk factorb 21 (78) 22 (61) 4 (29) 4 (31) 0.004
Abbreviations: OHSS, ovarian hyperstimulation syndrome; IVF, in vitro fertilization; BMI, body mass index.
a Inclusion criteria: previous OHSS; previous cycle cancelation due to high response; a prior IVF cycle with 15 follicles; a young woman with male or unexplained
infertility starting her first cycle.
b Previous OHSS, anovulation, polycystic ovary syndrome, BMI<20 kg/m2, or age<25.
Group differences were analyzed by using one-way ANOVA for parametric variables; Kruskal–Wallis tests for nonparametric variables; and Chi-Square test for categorical
variables; *p<0.05.
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Reactive Protein Gen.31, Roche Diagnostics, Rotkreuz,
Switzerland) on a Modular Analyzer1 (Hitachi Ltd., Tokyo, Japan)
was used; detection limit 3 mg/L.
We analyzed the data using SPSS for Windows1 (version 18).
Values above or below the detection limit were given an arbitrary
value, either twice the upper detection limit or 0.5 times the lowest
detection limit, respectively. Distribution of the variables was
assessed by the Shapiro–Wilk test. Statistical tests between and
within the groups are specified in the Tables and Figures. For
correlations, we used Pearson’s or Spearman’s coefficient tests.
Data are expressed as median; inter-quartile range (IQR) or
mean  standard deviation (SD) unless otherwise stated. The level of
significance was p < 0.05.
The main outcome measure was CRP. Post hoc power analysis
revealed that at OPU2 we had 93% power (1  b) to detect the
difference in the CRP levels between the controls and early OHSS
when the a-level was set at 0.05. The diagnostic accuracy of CRP for
early OHSS at the emergency polyclinic was analyzed by receiver-
operating characteristic (ROC) curve analysis and expressed as the
area under the curve (AUC).Table 2
The treatment characteristics. The data are indicated as [11_TD$DIFF]patient number[1_TD$DIFF] ( [12_TD$DIFF]%)[2_TD$DIFF] or [3_TD$DIFF] median
Control cycle Early OHSS
n 27 36
Agonist protocol [5_TD$DIFF]27 (100) 23 (64)
Starting FSH dose (IU) [4_TD$DIFF]150 (137–163) 150 (125–175)
Cumulative FSH dose (IU) [4_TD$DIFF]1500 ( [7_TD$DIFF]1275 [13_TD$DIFF]–1725) 1288 (1063–1513)
Triggering dose (IU)
hCG 5000 9 (33) 33 (92)
hCG 10,000 18 (67) 3 (8)
GnRH analog 0 0
Luteal supporta [10_TD$DIFF] [8_TD$DIFF]26 (96) 19 (53)
Follicles at OPU [4_TD$DIFF]19 (12–26) 37 (27–47)
Ovum count [4_TD$DIFF]11 (7–16) 20 (13–27)
Transferred embryos
No transfer 1 (4) 17 (47)
One embryo 25 (93) 18 (50)
Two embryos 1 (4) 1 (3)
Pregnancy rate [5_TD$DIFF]12 (46) 7 (37)
Abbreviations: OHSS, ovarian hyperstimulation syndrome; IVF, in vitro fertilization; FSH
transfer; OPU, ovum pick-up; GnRH, gonadotrophin releasing hormone.
[16_TD$DIFF]a Vaginal progesterone after embryo transfer.
[14_TD$DIFF]b One patient had additional hCG.
[15_TD$DIFF]c One twin pregnancy.
Group differences were analyzed by using one-way ANOVA for parametric variables; K
variables.Results
The clinical characteristics of the study groups were otherwise
comparable, but patients with early OHSS were younger than the
controls (Table 1). All patients were generally healthy, asthma
being the most common complaint (7%). A known risk factor for
OHSS (Table 1) was associated with early OHSS (p = 0.04 vs. late
OHSS). The severe or critical forms of OHSS were more frequent
with late than early OHSS (79% vs. 25%, p = 0.001). Early OHSS was
characterized by a higher number of follicles and retrieved oocytes,
as well as preventive procedures (more antagonist cycles, lower
cumulative doses of gonadotrophins, and fewer embryo transfers)
than the other groups (Table 2).
The symptomatically worst day on the ward with early OHSS was
OPU5 (range 2–8); OPU16 (13–32) with late OHSS; and OPU2 (0–8)
with other IVF complications. Eight patients were febrile, four of
whom had early OHSS with infection, the rest with other IVF
complications. Twelve patients received antibiotics: eight with early
OHSS, one with late OHSS, and three with other IVF complications.
Three patients underwent laparoscopy: one with early OHSS and
ovarian torsion and two as intra-abdominal bleedings.(inter-quartile range) [4_TD$DIFF].
Late OHSS Other IVF complication
14 13 p-Value
11 (79) 9 (69) 0.006
150 (109–191) 163 (138–188[6_TD$DIFF]) 0.070
1688 (1175–2201) 2000 (1325–2675) 0.002
[5_TD$DIFF]<0.001
7 (50) 6 (46)
7 (50) 6 (46)
0 1 (8)
14 (100)b [14_TD$DIFF] 10 (77) <0.001
21 (18–24) 16 (11–21) <0.001
17 (16–19) 11 (9–13) <0.001
[5_TD$DIFF]0.014
0 3 (23)
11 (79) 9 (69)
3 (21) 1 (8)
14 (100) 6 (60)c[15_TD$DIFF] 0.002
, follicle stimulating hormone; hCG, human chorionic gonadotrophin; ET, embryo
ruskal–Wallis test for nonparametric variables; and Chi-Square test for categorical
Table 3
Laboratory parameters on admission according to the study group. The data are expressed as median (inter-quartile range) if not otherwise stated.
Early OHSS Late OHSS Other IVF complication p-Value Control cycle p-Value vs early OHSS
n 36 14 13 27
Days after OPU OPU3 (1–8)a OPU13 (8–17)a OPU2 (0–7)a OPU2-3
CRP (mg/L) 21 (8–33)# 6 (3–9)# 3 (<3–27) 0.009 5 (<3–22) <0.001
WBC (E9/L) 13.6 (11.4–15.8) 11.7 (9.9–13.5) 12.1 (8.9–15.3) 0.191 9.5 (5.4–13.5) <0.001
HCT (%) 41 (38–44)* 43 (37–48)*2 38 (34–42)*,*2 0.030 39 (34–43) 0.038
PLC (E9/L) 256 (214–298)# 343 (271–415)#,#2 218 (180–257)#2 <0.001 257 (191–485) 0.912
E2 (nmol/L) 9.6 (5.8–13.4)# 7.3 (5.4–9.2)** 3.4 (1.2–5.6)#,** <0.001 3.7 (1.2–9.3) <0.001
Alb (g/L) 35.1 (32.1–38.1) 32.3 (29.4–35.3)# 37.4 (35.5–39.3)# 0.002 N.A.
Na (mmol/L) 135 (132–138) 136 (134–138) 136 (134–136) 0.370 N.A.
Abbreviations: OHSS, ovarian hyperstimulation syndrome; IVF, in vitro fertilization; OPU, ovum pick-up; CRP, C-reactive protein; WBC, white blood cell count; HCT,
hematocrit; PLC, platelet count; E2, estradiol; Alb, albumin; Na, sodium, N.A. not available.
Normal ranges: CRP<3 mg/L; WBC 3.4–8.2 E9/L; HCT 35–46%; PLC 150–360 E9/L; Alb 36–48 g/L; Na 137–145 mmol/L.
*2/#2
[17_TD$DIFF]: 2 indicates another pair differing with similar (* or #) significance in the comparison.
a Median (range).
Group differences were analyzed by one-way ANOVA followed by Tukey or Games Howell post hoc tests for parametric variables; Kruskal–Wallis test and Mann–Whitney U
test for non-parametric variables. *p0.05, **p0.01, and #p0.001.
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with early than late OHSS or the controls (Table 3). The CRP levels
did not differ between agonist and antagonist protocol treated
patients (data not shown), and did not correlate with the oocyte
count in early OHSS. If early OHSS was accompanied with signs of
infection, the CRP was higher (55; 29–80 mg/L) than without
infection (16; 6–27 mg/L, p = 0.002), similarly to other infectious
IVF complications (38; 4–73 mg/L, p = 0.48). In the ROC analysis,
the AUC was 0.74 (p = 0.001) with sensitivity of 69% and specificity
of 71% for a cut-off CRP of 12 mg/L for early OHSS.
Hematocrit levels exceeded 45% in seven of 20 (35%) severe/
critical cases. Platelet count (PLC) levels were higher with late than
early OHSS or other complications (Table 3). Thrombocytosis
correlated to the severity of OHSS (r = 0.31, p = 0.04). Hypoalbu-
minemia was worse in severe/critical OHSS (31.4; 29.6–33.3 g/L)
than in moderate OHSS (36.8; 34.0–39.6 g/L, p < 0.001).
In control IVF cycles (Fig. 2) CRP levels increased from
undetectable at mid-luteal phase to a peak of 5 (<3–9) mg/L at
OPU2 (p = 0.001) followed by a decrease to 3 (<3–6) mg/L at OPU7
(p = 0.03), and to undetectable at OPU14. CRP did not correlate
with BMI and the levels were similar in pregnant and non-pregnant
patients (data not shown). Of the other parameters, hematocrit,
white blood cell count, PLC, and albumin varied significantly, but
within normal limits. CRP level at OPU, (but not at OPU2),
correlated to the ovum count (r = 0.42, p = 0.03).
When analyzing CRP in the course of the disease (OPU-related
data, Fig. 3), the CRP level in early OHSS was higher than in the
controls at OPU2 (28; 10–46 mg/L, p < 0.001), and OPU7 (17; 9–
25 mg/L, p = 0.001, without infection), and reached control levels at
discharge (11;<3–23 mg/L). In late OHSS, the CRP level peaked to 8
(<3–18) mg/L, decreased to 6 (<3–11) mg/L at discharge, and was
7 (3–11) mg/L at the follow-up visit. Peak CRP was the highest
when early OHSS was complicated with infection (108; 49–
166 mg/L; without infection 20; 8–32 mg/L, p < 0.001), (Fig. 4).
BMI or the drainage of ascites (n = 23, 59%) or pleural fluid (n = 5,
13%) had no systematic effect on the CRP level. CRP levels after OPU
were not affected by IVF treatment outcome (data not shown).
The mean PLC exceeded that of the controls after OPU10 in both
late OHSS and in the other IVF complications groups. Plasma
albumin levels at OPU7 in early OHSS were lower than in the
controls (p < 0.001) and remained lower during the entire follow-
up. The most serious hypoalbuminemia occurred in late OHSS at
OPU16-21 (Fig. 3).
Comments
This prospective study shows that the majority of IVF
complications, within a week after OPU, are associated with anelevated CRP response beyond the level induced by OPU, whereas
in late OHSS, the CRP response is more stable.
To obtain reliable interpretation of CRP levels in women under
IVF treatment we recruited women with clinical risk factors for
OHSS. We detected that retrieval of multiple follicles and oocytes
induced a peak in CRP at two days after OPU, doubling the pre-
treatment level. This CRP response is probably due to the tissue
damage and inflammation induced by OPU, ovulation and
formation of multiple corpora lutei, and is well in line with earlier
studies showing a rise from the day of hCG injection to OPU [18,19]
and to the day of embryo transfer [20]. Contrary to some studies
[21,22], we found a significant decrease, instead of an increase, in
CRP from OPU2 to OPU7. As the half-life of CRP is around 19 h [13],
the decrease we found is well in line with the postoperative decline
after uncomplicated abdominal surgery [14]. Probably less
traumatic OPU and the use of vaginal, not intramuscular, luteal
support explain the difference between the studies.
The two to three times higher CRP levels in early OHSS than in
the controls, is in line with one earlier study [23]. However,
distinguishing early OHSS from infective complications at the
emergency polyclinic is difficult. This is also reflected in the ROC/
AUC analysis (cut-off value CRP 12 mg/L) for early OHSS, as
infections usually exceed this level. Further, fever (>38 8C) has
been associated with early severe OHSS in up to half of the patients
[24] making the differential diagnosis of infections more compli-
cated. Thus, the decision of antibiotic treatment requires follow-up
and consideration of other risk factors for infection, such as
puncture of endometriomas or tubal disease, as well as results of
urine and possibly blood cultures. However, there is clinical need
to search for novel biomarkers for infections [25].
The majority of our severe cases had late OHSS with low CRP
levels. The association between severity and late OHSS agrees with
a previous study [26]. Another study [27] explained the severity
with multiple pregnancies, which was not a factor in this study
with mostly singletons. Patients with late OHSS had noticeably less
clinical risk factors for OHSS than those with early OHSS, in line
with an earlier study [26], further emphasizing the distinct nature
of these two forms of OHSS.
In our series, one patient had early OHSS with a rising CRP level
from 100 to 150 mg/L (OPU2-4), but no signs of clinical infection or
other complications. She had an uneventful surveillance without
antibiotics. Another patient with previous mild asthma was
treated on the internal medicine ward as pneumonia due to
severe breathing difficulties and pleural fluid before diagnosing
late OHSS, highlighting the accurate diagnostics and knowledge of
OHSS symptoms in emergency polyclinics.
Hemoconcentration (hematocrit 45%) as a traditional marker
of severe OHSS is arguable as only one third of our patients met this
[(Fig._2)TD$FIG]
Fig. 2. C-reactive protein (CRP), white blood cell count (WBC), hematocrit (HCT),
platelet count (PLC), and plasma albumin (Alb) levels during uncomplicated IVF
cycle in women at risk of developing ovarian hyperstimulation syndrome (OHSS).
Time points are the mid-luteal phase (ML) prior suppression, one to three days
before human chorionic gonadotrophin injection (hCG), ovum pick-up (OPU),
embryo transfer (ET), and the days after oocyte retrieval (OPUd). The gray area
indicates the normal range of the laboratory values. Albumin levels are shown in
pregnant (dashed line) and non-pregnant women. No other pregnancy related
findings existed. Pairwise analyses were done by repeated measures ANOVA or
Wilcoxon signed rank test. The data are expressed as mean  standard error of
mean; *p < 0.05, **p  0.01, and ***p  0.001.
[(Fig._3)TD$FIG]
Fig. 3. C-reactive protein (CRP), white blood cell count (WBC), hematocrit (HCT),
platelet count (PLC), and plasma albumin (Alb) levels after oocyte pick-up (OPU),
during the course of early and late ovarian hyperstimulation syndrome (OHSS),
other IVF complications, or during uncomplicated IVF cycle. The OHSS cases
complicated with infection were excluded from the analysis. The gray area indicates
the normal range of the laboratory values. Group differences were analyzed by
Student’s t-test or Mann–Whitney U-test. The data are expressed as
mean  Standard Error of Mean; *p < 0.05, **p  0.01, and ***p  0.001 (compared
with uncomplicated IVF cycle).
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[(Fig._4)TD$FIG]
Fig. 4. Peak C-reactive protein (CRP) levels in the early IVF complications. The box represents the inter-quartile range, the line inside indicates the median CRP, and the
whiskers represent the first and fourth quartile. * Represents the outliers. OHSS, ovarian hyperstimulation syndrome; OPU, oocyte pick-up. Group differences were analyzed
by Kruskall–Wallis and Mann–Whitney U test. *p  0.01, **p  0.001 between the groups or compared with uncomplicated IVF cycle.
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recommendation to take care of fluid balance during IVF treatment,
especially with OHSS symptoms. To our knowledge, only little is
known about platelet levels during OHSS or the IVF cycle, although
platelets are known to have a role in corpus luteum formation
[28]. Our finding of elevated PLC levels from 10 days to over a
month after OPU, especially in late OHSS, and the association of PLC
level and the severity of the syndrome may relate to inflammatory,
interleukin-6 induced PLC formation from bone marrow [29], as
elevated interleukin-6 levels have been detected in OHSS
[30]. However, thrombocytosis as a marker of hemoconcentration
[7] was not supported, as hemodilution and thrombocytosis
occurred simultaneously in patients with late OHSS.
A limitation of our study is the small number of IVF
complications other than OHSS to evaluate the differences in
laboratory parameters in those. It can also be argued that we miss
data on the anti-Müllerian hormone in risk factor assessment for
OHSS, as it was not in general use at that time. Additionally, the
control IVF cycles give no data from antagonist cycles and agonist
triggering, a current method used to prevent imminent OHSS
[31,32]. However, we think, that the reduced dose agonist cycles
show us the best reference levels for emergency polyclinics, as
antagonist cycles are supposed to induce less systemic inflamma-
tion [19,33]. Further, we could compare most samples of acute
patients to the controls after OPU up to OPU14 and at OPU35. To
our knowledge, comparisons with this extent have not been
reported. We also reached all the most severe IVF complications of
the area at our tertiary clinic.
IVF complications offer a diagnostic challenge to the clinician
on duty. Knowledge of the day of admission according to OPU and
the progress of the preceding IVF protocol is of utmost importance
for interpreting laboratory results when evaluating possible IVF
complications. Caution is also needed in the interpretation of CRP
level with obesity and pregnancy, as these conditions have been
associated with elevated levels of inflammatory markers [34–
36]. However, the possibility of OHSS, early or late, should always
be considered.
In conclusion, without other signs of infection, elevated CRP
indicates follow-up, but is not an indication to prescribeantibiotics. We suggest that, a clinically elevated CRP level
(>10 mg/L) in the first week after OPU is indicative for early
OHSS and/or infection in IVF patients, whereas later, increased
platelet count and hypoalbuminemia in patients with embryo
transfer, support the diagnosis of late OHSS. Any of these findings,
with or without hemoconcentration, indicates follow-up.
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